Hostname: page-component-745bb68f8f-b95js Total loading time: 0 Render date: 2025-01-10T07:34:39.330Z Has data issue: false hasContentIssue false
  • English
  • Français

Early experience of the use of olanzapine across three rehabilitation services

Published online by Cambridge University Press:  02 January 2018

Paul Wolfson ,
Carol Paton ,
Phillip Steadman ,
Humphrey Needham-Bennett  and
Susan Cope
Paul Wolfson
Affiliation:
Oxleas NHS Trust, Pharmacy Department, Bexley Hospital, Old Bexley Lane, Bexley, Kent DA5 2BW
Carol Paton
Affiliation:
Oxleas NHS Trust, Pharmacy Department, Bexley Hospital, Old Bexley Lane, Bexley, Kent DA5 2BW
Phillip Steadman
Affiliation:
Oxleas NHS Trust
Humphrey Needham-Bennett
Affiliation:
Guy's & Lewisham NHS Trust
Susan Cope
Affiliation:
Guy's & Lewisham NHS Trust
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Aims and method

To monitor the effect of the introduction of olanzapine under naturalistic conditions to patients with severe and enduring mental Illness in three rehabilitation services.

Results

Thirty patients were prescribed olanzapine during the first six months of its launch. Objective ratings were used. Six months later, one-third were no longer on treatment one-third were unchanged and one-third had made useful clinical gains.

Clinical implications

Patients who have suffered from neurological or prolactin-related side-effects may benefit from treatment with olanzapine. Attitudes to treatment and adherence may improve.

Type
Original Papers
Information
Psychiatric Bulletin , Volume 23 , Issue 8: The Journal of Trends in Psychiatric Practice , August 1999 , pp. 480 - 483
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 1999 The Royal College of Psychiatrists

References

Barnes, T. R. E. (1989) A rating scale for drug-induced akathisia. British Journal of Psychiatry, 154, 672 676.CrossRefGoogle ScholarPubMed
Davies, L. M. & Drummond, M. F. (1994) Economics and schizophrenia: the real cost. British Journal of Psychiatry, 165 (suppl. 25), 18 21.CrossRefGoogle Scholar
Guy, W. (1976) The Clinical Global Impression Scale . ECDEU Assessment Manual for Psychopharmacology, revised DHEW Publ. No. (ADM) 78–388. Rockville. MD: National Institute of Mental Health.Google Scholar
Meltzer, H. Y. (1992) Dimensions of outcome with clozapine. British Journal of Psychiatry, 160 (suppl. 17), 46 53.CrossRefGoogle Scholar
Overall, J. E. & Gorham, D. R. (1962) The Brief Psychiatric Rating Scale. Psychological Reports, 10, 799 812.CrossRefGoogle Scholar
Simpson, G. M. & Angus, J. W. S. (1970) A rating scale for extrapyramidal side-effects. Acta Psychiatrica Scandinavica, 212 (suppl. 1), 11 19.CrossRefGoogle ScholarPubMed
Taylor, D., Holmes, R., Hilton, T., et al (1997) Evaluating and improving the quality of risperidone prescribing. Psychiatric Bulletin, 21, 680 683.CrossRefGoogle Scholar
Taylor, D., Drummond, S. & Pendlebury, J. (1998) Olanzapine in practice. Psychiatric Bulletin, 22, 552 554.CrossRefGoogle Scholar
Tollefson, G. D., Beasley, C. M., Tran, P. V., et al (1997) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry, 154, 457 465.Google ScholarPubMed
Weiden, P., Rapkin, B., Mott, T., et al (1994) Rating of Medication Influences (ROMI) Scale in schizophrenia. Schizophrenia Bulletin, 20, 297 310.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.